热门资讯> 正文
Trovagene to become Cardiff Oncology on May 8
2020-05-06 22:51
Reflecting its focus on cancer candidate onvansertib, Trovagene (TROV -4.0%) will change its name to Cardiff Oncology effective at the open on Friday, May 8.
On the executive management front, CSO Mark Erlander, Ph.D., promoted to CEO succeeding Dr. Thomas Adams who will transition to Executive Chairman.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
